1. Home
  2. DCTH vs GILT Comparison

DCTH vs GILT Comparison

Compare DCTH & GILT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCTH
  • GILT
  • Stock Information
  • Founded
  • DCTH 1988
  • GILT 1987
  • Country
  • DCTH United States
  • GILT Israel
  • Employees
  • DCTH N/A
  • GILT N/A
  • Industry
  • DCTH Medical/Dental Instruments
  • GILT Radio And Television Broadcasting And Communications Equipment
  • Sector
  • DCTH Health Care
  • GILT Technology
  • Exchange
  • DCTH Nasdaq
  • GILT Nasdaq
  • Market Cap
  • DCTH 630.4M
  • GILT 381.2M
  • IPO Year
  • DCTH N/A
  • GILT 1993
  • Fundamental
  • Price
  • DCTH $13.57
  • GILT $7.27
  • Analyst Decision
  • DCTH Strong Buy
  • GILT Strong Buy
  • Analyst Count
  • DCTH 4
  • GILT 2
  • Target Price
  • DCTH $24.00
  • GILT $8.50
  • AVG Volume (30 Days)
  • DCTH 734.6K
  • GILT 455.1K
  • Earning Date
  • DCTH 08-04-2025
  • GILT 08-06-2025
  • Dividend Yield
  • DCTH N/A
  • GILT N/A
  • EPS Growth
  • DCTH N/A
  • GILT N/A
  • EPS
  • DCTH N/A
  • GILT 0.24
  • Revenue
  • DCTH $53,850,000.00
  • GILT $321,407,000.00
  • Revenue This Year
  • DCTH $155.42
  • GILT $42.88
  • Revenue Next Year
  • DCTH $37.93
  • GILT $13.26
  • P/E Ratio
  • DCTH N/A
  • GILT $29.26
  • Revenue Growth
  • DCTH 1068.87
  • GILT 13.49
  • 52 Week Low
  • DCTH $7.17
  • GILT $4.04
  • 52 Week High
  • DCTH $18.23
  • GILT $8.05
  • Technical
  • Relative Strength Index (RSI)
  • DCTH 38.26
  • GILT 63.68
  • Support Level
  • DCTH $12.98
  • GILT $6.24
  • Resistance Level
  • DCTH $14.18
  • GILT $7.20
  • Average True Range (ATR)
  • DCTH 0.68
  • GILT 0.23
  • MACD
  • DCTH -0.28
  • GILT 0.11
  • Stochastic Oscillator
  • DCTH 15.95
  • GILT 79.70

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About GILT Gilat Satellite Networks Ltd.

Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.

Share on Social Networks: